ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) Return on equity 2016–2024
ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-597.6%FY2024 · since FY2016: -43.1% → -597.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -597.6% | -309.5 pp |
| FY2023 | -288.2% | -86.1 pp |
| FY2022 | -202.1% | -125.3 pp |
| FY2021 | -76.8% | -38.6 pp |
| FY2020 | -38.1% | +72.8 pp |
| FY2019 | -110.9% | -72.3 pp |
| FY2018 | -38.7% | -4.1 pp |
| FY2017 | -34.6% | +8.5 pp |
| FY2016 | -43.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ADAPY financial trends
ADAPY RevenueADAPY Net incomeADAPY Net marginADAPY Gross profitADAPY Gross marginADAPY Operating incomeADAPY Operating marginADAPY Operating cash flowADAPY Free cash flowADAPY Capital expendituresADAPY Stock buybacksADAPY Dividends paidADAPY Total assetsADAPY Total liabilitiesADAPY Shareholders’ equityADAPY overview →